Skip to main content
. 2021 Feb 24;12:616858. doi: 10.3389/fphar.2021.616858

FIGURE 5.

FIGURE 5

HBV DNA Reduction compared to baseline between wild-type control and heterozygote cases among CHB patients using first-line NAs.